Cosentyx® IV

Understanding Cosentyx® IV
Cosentyx® (secukinumab) is a monoclonal antibody that targets interleukin‑17A (IL‑17A), a cytokine involved in inflammatory immune responses. It is indicated for the treatment of certain autoimmune and inflammatory conditions and is available as an intravenous (IV) infusion option for adults with specific rheumatologic diseases.

How Cosentyx® IV Works:

• Binds to and neutralizes interleukin‑17A (IL‑17A), preventing it from interacting with its receptor and thereby inhibiting IL‑17A–mediated inflammatory responses.
• Helps reduce signs and symptoms of active psoriatic arthritis, ankylosing spondylitis, and non‑radiographic axial spondyloarthritis in adults by decreasing inflammation.
• Is administered as a weight‑based intravenous infusion by a healthcare professional.
• Represents an IV formulation of a human interleukin‑17A antagonist with established use in subcutaneous form for multiple indications.

FDA Approval:

2015 – Initial U.S. FDA approval of Cosentyx® (secukinumab) for adults with moderate to severe plaque psoriasis (subcutaneous formulation).

2016 – FDA approval expanded to include adults with active psoriatic arthritis and adults with ankylosing spondylitis (subcutaneous formulation).

2020 – FDA approval expanded to include adults with non‑radiographic axial spondyloarthritis (subcutaneous formulation).

2023 – FDA approval of an intravenous (IV) formulation of Cosentyx® for adults with psoriatic arthritis, ankylosing spondylitis, and non‑radiographic axial spondyloarthritis.

For more information, please visit the Cosentyx® IV patient website. Speak with your healthcare provider to determine if Cosentyx® IV is the right treatment option for you.